Generate Biomedicines (GENB) logo

Generate Biomedicines (GENB) stock

Protein medicines , market cap $1.3B

After-hours Fri
$9.90
+3.77%

Close $9.54 -8.00%

Why is GENB down?

Down 33% from Nov 9 to Nov 20 while the S&P 500 fell 8%.

  • Its Nov 12 results: net loss widened to $87.7M, from $60.0M a year before; research and development expenses were $82.3M, from $62.2M. It fell 7% on Nov 12.

Sources: Price history, Nov 20, 2026; Company release, Nov 12, 2026

−2Volatility moves 11.4% a day with no profit or positive free cash flow over four quarters on file

Tell me next time GENB moves

Free account, no card. An optional alert when GENB moves or its score changes.Pro, $1 for a first month. An optional alert when GENB moves or its score changes.Pro, 7 days free with a card. An optional alert when GENB moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on GENB →2 more reasons why GENB fell 33% since Nov 9, from its filings, with the other side, the timeline, and its peers, for Pro members.
Quality Score
-1
Poor
In its industry
#113of 273
Checks firing
1of 14
Transition
From its high
-57.9%
under its best since listing

GENB's Quality Score fell 1 point on Fri, Nov 20, to -1. It did not trade higher than the day before.

New listing, trading since Feb 27, 2026. 186 trading days so far, so 1 of the 14 chart checks waits for more history.

Follow GENB's trial news. Pro members can get an alert when Generate Biomedicines files news, and see its trials, share raises, and its CEO's filings.

Get an alert when GENB files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2026“The first patient is expected to be dosed in 2026.”Trial start · SEC filing · Aug 6

Key facts on GENB

Key facts on GENB
Holding it backMoves 11.4% a day with no profit behind it
Latest filing8-K, Nov 12 Reported its quarterly results

GENB in the news

Thu Nov 12Form 8K Generate Biomedicines For: 12 November By Investing.com ca.investing.com and 1 more · yesterday 7:29 AM ET GENB closed −6.8% that day.

What's next

Sat Feb 27: One year since its IPOListed Feb 27, 2026 at $16.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

GENB catalysts

Coming up

After its last 3 reports it closed -7.4% on average, higher 0 of 3 times.

What's next for GENB, and how long its cash lasts

Next step the company has named

2026“The first patient is expected to be dosed in 2026.”Trial start · SEC filing · Aug 6

What it means: when a trial begins, or reaches the stage the company named.

A trial underway
GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled AsthmaPhase 3 · Recruiting · 786 people · main data estimated Dec 2028 · NCT07276724

4 more trials, 5 filings, for Pro members.

Cash runway Sep 30 balance sheet

$404M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into the first half of 2028” (8-K, Nov 12).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director Frances Arnold sold 11,409 shares on Oct 29, under a planned sale. 6 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Michael Nally’s 6 filings and quotes.

Get an alert when GENB files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How GENB ranks in Biotech

GENB is #113 of 273 by Quality Score.

How GENB ranks in Biotech
RankStockQuality Score
113Generate Biomedicines (GENB) logoGENBGenerate Biomedicines-1

More in Biotech

When does GENB report earnings, and what happens after?

Expected to report Thu Mar 25, before the open (in 124 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What GENB reported on Nov 12, 2026

The quarter

A loss of $0.68 a share.

“This revenue reflects developments in the ongoing Amgen and Novartis research programs and that Generate is near completion of its performance obligations under both agreements.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

GENB's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The increase was driven primarily by continued investment in the GB-0895 Phase 3 SOLAIRIA clinical trials in severe asthma and was partially offset by a decrease in external discovery and other program related costs.”

From its results filing (SEC filing · Nov 12)

1 more sentence, for Pro members.

The numbers

Market value
$1.3B
today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on GENB: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-11.2%-4.1%-6.8%
May 7Aug 6Nov 12
ReportedGapReaction5
days
Nov 12, 2026Before open-6.6%-6.8%-23.1%
Aug 6, 2026Before open-2.7%-4.1%+4.1%
May 7, 2026Before open-3.4%-11.2%+6.0%

GENB closed higher after 0 of its last 3 reports.

GENB has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on GENB, and all 14 on every stock.Get in free →See the top 3 →Start Pro

GENB RSI on Nov 20: 33.3, below its 50-day average

Not scored

RSI 33.3, MACD below signal. Not scored.

3 more findings on GENB, each with its source, for Pro members.

GENB share count over time

Shares: 3.9 times the count a year ago (to Sep 30).

Shares of GENB outstanding, as filed
Shares
outstanding
As
of
129.1MOct 29, 2026
128.4MJul 29, 2026
128.2MApr 29, 2026
Offerings, shelves, and splits of GENB, from its filings
From its
filings
Filed
Raised $400M in a sale of shares, about 30% of its market valueFeb 27, 2026
Registered shares for sale (S-1)Feb 4, 2026

GENB's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold GENB?

In ETFs: GENB is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Generate Biomedicines

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Somerville, MAgeneratebiomedicines.com

Listed on Nasdaq on Feb 27, 2026, and is 40% below its $16 offer price now. Its IPO filing and first days

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on GENB and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn GENB's score around: 4 things
  • 3 more filings explained, a plain line each
  • Real-⁠time prices, no delay

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: GENB's Quality Score is -1 (Poor), #113 of 273 in Biotech.

What does GENB's Quality Score say?

GENB scores -1 today, which Breakaway calls Poor. It is #113 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 33% from Nov 9 to Nov 20 while the S&P 500 fell 8%. Shares: 3.9 times the count a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is GENB's Quality Score?

GENB scores -1 today, which Breakaway calls Poor (below zero). That is #113 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind GENB's -1.

When does GENB report earnings?

Expected to report Thu Mar 25, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. GENB closed higher after 0 of its last 3 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Generate Biomedicines: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.